YEEHAW CANDIDATES Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sergio H who wrote (963)	1/15/2003 12:05:30 AM
From: Mike	Read Replies (2) of 23958

Would love some on the board to take a look at one of the YEEHAW'S on the list. The name of the company is The Medicines Company (MDCO). This has been a yeehaw stock that has more room to move. First below is the web site for the company. Most if not all of the information that I am going to discuss is here on the site. themedicinescompany.com The company went public in June 2000 at a price of $16. The company got its start with acquisition on a product from Biogen that was not yet FDA approved. The drug was called Bivalirudin. This product was renamed Angiomax and received FDA approval in Dec 2000. MDCO stock rose to a high of approx $30. The reason why Biogen sold it is that the clinical data they collected did not show great beneficial data for the associated cost of the Bivalirudin. Well what happened is when Biogen was testing it the therapy that it was being used with was changing too fast. That therapy was coronary angioplasty. By the time Biogen got done collecting data the practice pattern had changed. What the people at The Medicine Company did was to relook at the trials Biogen had completed and "recut" or took a relook at the data. Well the data looked good as measured againest current practices. The right clinical trial had to be written and major big name institutions had to do the trial. Well that is when they designed the trial called REPLACE. Once the REPLACE trial was completed the trial REPLACE II was started. Below is a press release on the release of the REPLACE II trial. yahoo.smartmoney.com This trial which was released on November 17,2002 was an absolute homerun. The company hit on all primary and secondary endpoints. The lead investigator was Eric Topel from Cleveland Clinic and the data site for analysis was Duke. The data is going to be published in the next month in the Journal of American Medical Association in mid Feb of 2003. I was hearing that it was supposed to be this week but it is going to be Feb. Following this data release sales of Angiomax have been on a upward rise. Sales prior to this were in the range of $2M-$2.5M per month. After the publication they have moved to an approx $5M for the month of Dec '02. On Dec 17,2002 the company had a conference call which is below: corporate-ir.net On this conference call they stated sales of Angiomax are ramping up and for '02 it looked like sales would come in at $38M. They made upward sales projections for '03 to between $70-$90M for the year. Lastly, the company presented at JP Morgan Healthcare Conference which was held on Jan 6th. That link is also below: mapdigital.com The company also has the following clinical activities for increased use of Angiomax. Low Molecular Weight Heparin (LMWH) Pre-treatment Study PK/PD Study Ticlopidine Interaction Study Hirulog® (now ANGIOMAX®) Early Reperfusion/Occlusion (HERO-2) Trial Comparison of Abciximab Complications with Hirulog (now ANGIOMAX®) Ischemic Events Trial (CACHET) Phase A CACHET Phase B CACHET Phase C Anticoagulant Therapy with Bivalirudin to Assist in PCI (ATBAT) 1st Inning Trial (PCI in HIT/HITTS) Drug Interaction Study — ANGIOMAX® plus Integrilin vs. heparin plus Integrilin in PCI Drug Interaction Study — ANGIOMAX® plus Aggrastat vs. heparin plus Aggrastat in PCI REPLACE Study — ANGIOMAX® in the modern PCI setting CABG Off-Pump Study — ANGIOMAX® in OPCAB Graft Surgery For information regarding clinical activities contact angiomax@themedco.com For Angiomax® Medical Information Requests (health care professionals only) call 1-800-ANGIOMAX (1-800-264-4662). The last item is a presentation that will take place this March. The data from the Replace II trial will be presented at the ACC Confernce in Chicago. This is where subset analysis will be released from Replace II. This could also give upward movement to the use of Angiomax and the stock. This is a very undercovered stock and company. Very few analyst cover the stock and it appears to me to be an undiscovered diamond. I would love to get help in determining what other companies have profiles similar to MDCO. What is the risk profile and what should the stock price be based on different scenarios. I just think with sales in '03 of between $70-$90M and eps in the range of -0.24 to -0.11 that the stock will have legs. It is expected to show a profit in '04. I think that if all the data is "cut and analyzed" and there are no gapping holes this one could be a major YEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEHAWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW!!!!!! Sorry for the long post and comments and questions encouraged, Mike PS In addition, if this detailed of a discussion should go to the MDCO board please let me know.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next